JP Morgan Maintains Overweight on Elevance Health, Lowers Price Target to $535
Portfolio Pulse from richadhand@benzinga.com
JP Morgan analyst Lisa Gill maintains an Overweight rating on Elevance Health (NYSE:ELV) but lowers the price target from $572 to $535.
July 07, 2023 | 1:08 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JP Morgan maintains an Overweight rating on Elevance Health but lowers the price target from $572 to $535, which may impact the stock's performance.
The news is directly about Elevance Health and its rating by JP Morgan. While the Overweight rating is maintained, the lowering of the price target might create some uncertainty among investors, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100